PT - JOURNAL ARTICLE AU - Tosif, Shidan AU - Lee, Lai-yang AU - Nguyen, Jill AU - Selman, Chris AU - Grobler, Anneke C AU - McMinn, Alissa AU - Steer, Andrew AU - Daley, Andrew AU - Crawford, Nigel TI - Less invasive SARS-CoV-2 testing for children: A comparison of saliva and a novel Anterior Nasal Swab AID - 10.1101/2022.09.21.22280208 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.21.22280208 4099 - http://medrxiv.org/content/early/2022/09/23/2022.09.21.22280208.short 4100 - http://medrxiv.org/content/early/2022/09/23/2022.09.21.22280208.full AB - Reducing procedural discomfort for children requiring respiratory testing for SARS-CoV-2 is important in supporting testing strategies for case identification. Alternative sampling methods to nose and throat swabs, which can be self-collected, may reduce laboratory-based testing requirements and provide rapid results for clearance to attend school or hospital settings. The aim of this study was to compare preference and diagnostic sensitivity of a novel anterior nasal swab (ANS), and saliva, with a standard combined nose and throat (CTN) swab. The three samples were self-collected by children aged 5-18 years who had COVID-19 or were a household close contact. Samples were analysed by reverse transcription polymerase chain reaction (RT-PCR) on the Allplex SARS-CoV-2 Assay. Most children and parents preferred the ANS and saliva swab over the CTN swab for future testing. The ANS was highly sensitive (sensitivity 1.000 (95% Confidence Interval (CI) 0.920, 1.000)) for SARS-CoV-2 detection, compared to saliva (sensitivity 0.886, 95% CI 0.754, 0.962). We conclude the novel ANS is a highly sensitive and more comfortable method for SARS-CoV-2 detection when compared to CTN swab.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05043623Funding StatementThis work was supported by a grant from Rhinomed Pty Ltd and the Victorian Department of Jobs, Precincts and Regions.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was by The Royal Children's Hospital Human Research Ethics Committee (HREC77305)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ANSAnterior Nasal SwabCOVID-19Coronavirus disease 2019CTNCombined Throat and Nose SwabRT-PCRReverse transcription polymerase chain reactionSARS-CoV-2severe acute respiratory syndrome coronavirus 2